Summary Soluble and nuclear oestrogen receptor status was determined in both the central and peripheral portions.of tumour for 37 cases of adenocarcinoma of the endometrium. Of these, 29 had functional receptor in the peripheral biopsy, but only 19 retained functional receptor in the centre. Six of the 10 patients whose tumours showed this difference came from the group of 12 patients who were immediately post-menopausal (4.50+ 1.45 y post-menopausal age). Receptor status was not related to tumour classification into histological grades I and II. However, receptor-negative central biopsies were significantly more likely (P<0.05) to be Grade III. Early relapse was also related to a receptor-negative central biopsy.
Several studies have approached the problem of intra-tumoural variation in oestrogen receptor status in breast cancer (Tilley et al., 1978; Silversward et al., 1980) . Others have demonstrated the advantages of measuring receptor in both soluble and pellet fractions of each biopsy (Laing et al., 1977; Barnes et al., 1979; Thorsen, 1979) . With the increased use of receptor status, both as an index of prognosis (Bishop et al., 1979; Hawkins et al., 1980; Leake et al., 1981b) , and in selection of therapy (Edwards et al., 1979; Hawkins et al., 1979; Leake et al., 1981a) , the optimum choice of tumour section for receptor assay has become very important in breast cancer management. Since it has been proposed that steroid receptor status has similar potential in the management of endometrial cancer (Pollow et al., 1975; Bayard et al., 1978; Feil et al., 1978; Prodi et al., 1979) , a close study of tumour sampling problems is indicated. We present an analysis of the intra-tumoural variation of both soluble and nuclear oestrogen receptor status in adenocarcinoma of the endometrium.
We report that comparison of the intra-and inter-tumour soluble and nuclear oestrogen receptor status is best made when expressed per unit DNA. Our results indicate that the concentration of receptor in each fraction of receptor-positive tumour is similar to that in normal endometrium. We report that tumours of histological grade III, more frequent in Sicily than elsewhere, are significantly more likely to be receptor-negative although receptor status does not distinguish Grades I and II. A significant proportion of tumours with receptor-positive peripheral biopsies have receptor-negative central biopsies, particularly in a group of patients who are immediately postmenopausal.
Materials and methods
All patients attended the Obstetric and Gynaecologic Clinic of the Policlinico or the Cancer Hospital Centre, Palermo. All tissue was obtained after hysterectomy. Obviously nectrotic tissue was discarded and then parallel sections removed for pathological examination and receptor assay. The latter were stored in 0.25 M Sucrose, 1.5 mM MgCl2, 10mM HEPES, pH 7.4, 50% Glycerol (v/v) at -20°C until use. This storage procedure has been found to maintain both concentration Leake, 1980) and molecular form (Hyder & Leake, in press) of oestrogen receptor for up to 60 days.
Where possible (37 cases out of 47) tumour tissue was sub-divided according to its location in situ.
Sub-sections were identified as (1) peripheral (p)-that taken from the so-called "growing" edge of the tumour (care was taken to avoid sections from areas of myometrial infiltration); and (2) central (c)-that taken from non-peripheral and, supposedly, older parts of the tumour. The term "central" is used for convenience only, since a physical centre for endometrial cancer is often difficult to define. Occasional intermediate pieces (i) were also retained from larger tumours in which the central part could be legitimately identified.
Oestrogen receptor assays were carried out on both the soluble and pellet fractions of each section of tissue. The assay (incorporating a 7-point Scatchard plot) measured specific, high affinity binding sites only and has been described in detail (Leake, 1980; Leake et al., 1981a Tumour tissue, confirmed pathologically as adenocarcinoma of the endometrium, was taken from 47 patients of whom 42 were postmenopausal. The post-menopausal group was subdivided into (1) those greater than and (2) those less than 6 y of post-menopausal age. Where possible, sections of pathologically "normal" endometrium was also dissected out. All other procedures were carried out as previously described (Leake et al., 1981a) . Where appropriate, data are quoted as mean + s.e. (no. of samples).
Results
The concentration of specific oestrogen receptor, as calculated by Scatchard analysis, in the soluble fraction is normally expressed per unit cytosol protein (Bayard et al., 1978; Soutter et al., 1979; Hawkins et al., 1980 Hunter et al., 1980) suggest that they are only sampling peripheral regions or, probably, small tumours. Functional oestrogen receptor, for the purposes of discussion, has been defined as the presence of measurable receptor in both the soluble and nuclear fractions of a biopsy (Leake, 1980; Leake et al., 1981a) . It has been demonstrated in breast cancer that the response rate to endocrine therapy is elevated to -70% by the inclusion of the ERn assay (Leake et al., 1981a) The distribution of patients by menopausal age (Figure 1 ) confirms only a small incidence of endometrial cancer in pre-menopausal women, a large incidence around menopause (postmenopausal age 0-6y, mean age 4.50+1.45 (12)) and then, perhaps, a second wave of high incidence in the later years after menopause (postmenopausal age >6 y, mean age 16.05 + 6.67 (20)). When the tumours were classified according to histological grading (Table IV) , it became apparent that the disease has frequently progressed considerably further at the time of hysterectomy than is true in other parts of Europe or the United States. In this study 28% of the patients had tumours which were relatively undifferentiated (histological grade III) whereas other recent studies (Feil et al., 1978; Prodi et al., 1979; Hunter et al., 1980) found only 10%, 4%, and 16% respectively to have Grade III disease. When receptor status of the central portion of each tumour was compared with histological grading (Table V) receptor status showed little relationship to Grades I and II but there was a significant (P<0.05) loss of oestrogen receptor in the poorly-differentiated tumours, confirming earlier trends (Pollow et al., 1975; Janne et al., 1979) .
In an attempt to correlate loss of oestrogen receptor with tumour growth, the oestrogen receptor status of both central and peripheral portions of each tumour was re-examined with respect to menopausal age (Table VI) . The tumours (Bross et al., 1968; Baum, 1977 Post-menopausal patients were divided into 2 groups of greater or less than 6y of post-menopausal age. Abnormal receptor status combines both (+/0) and (0/+) patients.
oestrogen receptor throughout the tumour and so should reflect a good chance of extended response to endocrine therapy.
Discussion
The success of oestrogen and progesterone receptor status as indices of both prognosis and potential response to endocrine therapy in breast cancer 0 C B (Edwards et al., 1979; Hawkins et al., 1980; Leake et al., 1981a) has led to attempts to use receptor status in the management of endometrial cancer. Preliminary results suggest that oestrogen and progesterone receptor status might well be useful in predicting response to endocrine therapy (Benraad et al., 1980) although this view does not yet have universal support (Hoffman & Siiteri, 1980) . The success of the various treatments of primary endometrial cancer (Hunter et al., 1980) have meant that data on the prognostic value of receptor status are very limited. However, in our study, 5 patients have so far relapsed and each has had a receptor-negative (0/0) result for the central portion of tumour although, in two cases, the peripheral portion was receptor-positive. In Sicily, endometrial cancer is often more advanced on first examination than it is in other countries. The tumours are often very large and more likely to be histologically classified as Grade III. It has, therefore, been possible to look at oestrogen receptor distribution across individual tumours in relation to growth patterns.
To compare concentration of receptor between different parts of the same tumour and between different tumours, it was found more meaningful to express both ERC and ERn content relative to the DNA content of the original homogentate.
Comparison of receptor content in the central and peripheral portions of the same tumour (Table 1) suggested that the peripheral portion is significantly more likely to contain functional oestrogen receptor than the central portion (P<0.02). This is consistent with the view that most endometrial cancer is initially hormone dependent but that the older parts of the tumour eventually lose dependence (a trend supported by the data on very large tumours- Table II) . Identification of the central part of the tumour as being the oldest part is convenient but, perhaps, inaccurate. In an equivalent study on large breast cancer biopsies (Silversward et al., 1980) , qualitatively similar conclusions were reported in that receptor concentration is low at the centre and much higher at the periphery of the tumour-although this is not always the case (Tilley et al., 1978) . A study of the receptor status of metastatic disease would be valuable in indicating which parts of the primary are most likely to give rise to secondary deposits.
Measurement of concentration of receptor (Table  III) indicates that loss of functional receptor is perhaps an all-or-none phenomenon rather than a gradual process, since those tumours which did contain receptor-positive central portions showed no trend to lower receptor concentration at the centre. This suggests that the growth patterns of breast and endometrial cancer may differ in this respect since the loss of receptor-containing cells in breast cancer seems to be more gradual (Silversward et al., 1980) . Abnormal receptor status was surprisingly common and, in particular, the occurrence of receptor in the nuclear fraction alone was much higher than that encountered in breast cancer (Leake et al., 1981a) . This might represent a stage in the loss of normal receptor function (Geier et al., 1980) or a related breakdown in the nuclear processing mechanism (Horwitz & McGuire, 1978) . A study of protease content and distribution might be of value. The similarity between mean receptor concentrations in normal and tumour tissue (Table  3 ) confirms previous observations (Gurpide et al., 1976; Pollow et al., 1977) . However, when patients in late post-menopause (>6 y) are considered relative to those in early post-menopause then there was a significant difference (P <0.01) in mean total receptor concentration (5.11 + 3.57 (12) fmol. jug-1 DNA compared with 2.69 + 0.76 (5)) possibly indicating an increased chance of response to hormone therapy and perhaps also a better prognosis for the late menopausal group.
The data comparing receptor status and histological grading confirmed that of most other workers (Pollow et al., 1975; Feil et al., 1978; Janne et al., 1979; Hunter et al., 1980) in showing that, apart from an increase in receptor-negativity in Grade III disease, receptor status and histological grade are unrelated. This study contained a much larger proportion of tumours of histological Grade III and so the tendency for them to be receptor-negative was significant for the first time.
Since the change from receptor-positive to receptor-negative status in biopsies from peripheral and central portions of the same tumour is very marked in the immediate post-menopausal disease (0-6 y, Table VI), it would be reasonable to suggest that this might indicate the onset of hormoneindependent disease typical of poorly-differentiated tissue. In fact, the proportion of patients in the 0-6 y post-menopausal group, who had Grade III tumours, was not significantly raised relative to the remainder. Further, since only 5 patients overall have so far relapsed it is not yet possible to say to what extent relapse is more rapid in receptornegative patients within this group, although preliminary data clearly suggest that a receptornegative central biopsy is an indication of an early relapse.
In conclusion oestrogen status of large endometrial cancers, particularly those from women immediately post-menopausal, can change from positive at the periphery to negative at the centre. The disease in women in this early post-menopausal group is very likely to lose hormonal dependence whereas hormone-dependent disease in older women is much less likely to changes. Where possible biopsies of both central and peripheral portions of endometrial cancer are recommended.
